|Day Low/High||196.00 / 201.38|
|52 Wk Low/High||166.30 / 244.99|
It's no secret that the Fed would like to get out of the short-term repo business.
What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
According to the charts, the drugmaker should break out to new highs.
These stocks are priced for total imperfection. That's just what you want.
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Before I give my recommendation I want to visit with the charts and indicators.
RMPIA is up 20.9% in the first nine months of 2019.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Let's check out the charts to get a sense of where prices could be headed.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.